MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Cytokinetics Company Profile (NASDAQ:CYTK)

Consensus Ratings for Cytokinetics (NASDAQ:CYTK) (?)
Ratings Breakdown: 7 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $18.29 (92.68% upside)

Analysts' Ratings History for Cytokinetics (NASDAQ:CYTK)
Show:
DateFirmActionRatingPrice TargetActions
6/21/2016FBR & Co.Reiterated RatingBuy$24.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/25/2016Piper JaffrayReiterated RatingOverweight$24.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/30/2016Roth CapitalReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/9/2016JPMorgan Chase & Co.Lower Price TargetMarket Outperform$16.00 -> $14.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$16.00 -> $14.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/17/2016Cowen and CompanyReiterated RatingBuy$16.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/24/2015MLV & Co.Reiterated RatingBuy$9.00 -> $14.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/30/2014 forward)
Earnings History for Cytokinetics (NASDAQ:CYTK)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
7/27/2016        
4/28/2016Q1($0.37)($0.31)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/16/2016Q415($0.32)($0.24)$10.49 million$9.80 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/29/2015Q315($0.30)($0.23)$11.24 million$7.90 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/30/2015Q1($0.12)($0.23)$10.10 million$4.40 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/12/2015Q4($0.17)$0.23$10.80 million$21.80 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/30/2014Q3($0.27)($0.16)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/30/2014Q2($0.32)($0.23)$7.01 million$7.80 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/6/2014Q1($0.34)($0.27)$7.69 million$8.00 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/6/2014Q4($0.08)$0.21$19.14 million$24.30 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Cytokinetics (NASDAQ:CYTK)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.33)($0.33)($0.33)
Q2 20161($0.39)($0.39)($0.39)
Q3 20161($0.42)($0.42)($0.42)
Q4 20161($0.44)($0.44)($0.44)
(Data provided by Zacks Investment Research)
Dividend History for Cytokinetics (NASDAQ:CYTK)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Cytokinetics (NASDAQ:CYTK)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
8/31/2015L Patrick GageDirectorBuy1,000$6.95$6,950.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/20/2015L Patrick GageDirectorBuy10,000$6.55$65,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/6/2015L Patrick GageDirectorBuy10,000$5.71$57,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/11/2015Andrew A WolffCMOSell21,875$7.80$170,625.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/30/2014Fady Ibraham MalikSVPSell21,630$6.73$145,569.90View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/9/2014L Patrick GageDirectorBuy10,850$4.09$44,376.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/25/2014Eastern Capital Ltdmajor shareholderBuy500,000$8.00$4,000,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Cytokinetics (NASDAQ:CYTK)
DateHeadline
06/30/16 03:49 PMCytokinetics Announces Start of Phase 2 Clinical Trial of CK-2127107 in Patients With Chronic Obstructive Pulmonary Disease
06/30/16 09:04 AMCytokinetics (CYTK) Commences CK-107 Crossover Trial in COPD - StreetInsider.com
06/29/16 03:30 PMCytokinetics, Incorporated Stock Momentum Hits Strength - CML News
06/29/16 03:30 PMHow Analysts Feel About Cytokinetics, Inc. (NASDAQ:CYTK)? - Press Telegraph
06/28/16 08:25 AMCovering the Bases on Cytokinetics, Incorporated (NASDAQ:CYTK): Where is the Stock Going? - Press Telegraph
06/26/16 08:36 AMCytokinetics May/June Presentations Suggest High Likelihood Of Success - Seeking Alpha
06/26/16 08:36 AMCytokinetics (NASDAQ:CYTK) Shorts Decreased by 1.77% After Short Covering - Press Telegraph
06/19/16 07:59 AMWhat Analysts say about Cytokinetics, Inc. (NASDAQ:CYTK)? - iStreetWire
06/16/16 07:53 AMCytokinetics Incorporated (CYTK) Jumps 6.78% on June 15 - Equities.com
06/16/16 03:05 AMCytokinetics (CYTK) Looks Good: Stock Adds 6.8% in Session -
06/15/16 08:21 AMCytokinetics to Participate in Upcoming Investor Conferences - GlobeNewswire (press release)
06/14/16 03:09 PMCytokinetics to Participate in Upcoming Investor Conferences - [at noodls] - SOUTH SAN FRANCISCO, Calif., June 14, 2016 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) announced today that Robert I. Blum, President and Chief Executive Officer, is scheduled to present at the ...
06/09/16 10:49 AMCytokinetics, Incorporated (NASDAQ:CYTK) Fundamental Star Rating Report - CML News
06/01/16 03:45 PMHow Analysts Feel About Cytokinetics, Inc. (NASDAQ:CYTK)? - HNN - How Analysts Feel About Cytokinetics, Inc. (NASDAQ:CYTK)?HNNOut of 6 analysts covering Cytokinetics (NASDAQ:CYTK), 6 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Cytokinetics has been the topic of 5 analyst reports since July 24, 2015 according to StockzIntelligence Inc. Below is a ...Broker Watchlist: Cytokinetics, Incorporated (NASDAQ:CYTK)Share Trading Newsall 2 news articles »
05/27/16 12:54 PMAre Analysts Bearish Cytokinetics, Inc. (NASDAQ:CYTK) After Last Week? - Wall Street Hints and News - Are Analysts Bearish Cytokinetics, Inc. (NASDAQ:CYTK) After Last Week?Wall Street Hints and NewsOut of 6 analysts covering Cytokinetics (NASDAQ:CYTK), 6 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Cytokinetics has been the topic of 5 analyst reports since July 24, 2015 according to StockzIntelligence Inc. Below is a ...Cytokinetics, Incorporated (NASDAQ:CYTK) Closes At $8.21Investor NewswireCytokinetics, Incorporated (NASDAQ:CYTK) Stock Update & EstimatesStock Tick TockCytokinetics, Incorporated (NASDAQ:CYTK): Analysts Quick Take on EarningsNews Tribuneall 4 news articles »
05/24/16 12:20 PMBroker Outlook For Cytokinetics, Incorporated (NASDAQ:CYTK) - Share Trading News - Broker Outlook For Cytokinetics, Incorporated (NASDAQ:CYTK)Share Trading NewsBroker Outlook For Cytokinetics, Incorporated (NASDAQ:CYTK). By Brenton Akerman / in US Broker Ratings / on Tuesday, 24 May 2016 01:18 PM / 0 Comments. The most recently updated broker views and price targets issued for Cytokinetics, Incorporated ...and more »
05/23/16 01:57 PMCytokinetics (CYTK) Provides Additional COSMIC-HF Data; Improvement in LV Systolic Function Noted - StreetInsider.com - Cytokinetics (CYTK) Provides Additional COSMIC-HF Data; Improvement in LV Systolic Function NotedStreetInsider.comCytokinetics, Inc. (Nasdaq: CYTK) announced that additional results from COSMIC-HF (Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure), a Phase 2b trial evaluating omecamtiv mecarbil in patients with chronic heart ...Cytokinetics, Incorporated (NASDAQ:CYTK) - Broker UpdateRisers & FallersBroker Outlook For The Week Ahead Cytokinetics, Incorporated (NASDAQ:CYTK)Share Trading Newsall 3 news articles »
05/23/16 06:47 AMCYTOKINETICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits -
05/23/16 06:46 AMCytokinetics Announces Presentation of Additional Results From COSMIC-HF at Heart Failure 2016 Congress - [at noodls] - Treatment with Omecamtiv Mecarbil Produced Progressive and Sustained Effects On Cardiac Function as Measured by Reductions in Diastolic Ventricular Volume and NT-proBNP SOUTH SAN FRANCISCO, Calif., May ...
05/22/16 01:15 PMCytokinetics (CYTK) Adds New Director - StreetInsider.com - Cytokinetics (CYTK) Adds New DirectorStreetInsider.comCytokinetics, Inc. (Nasdaq: CYTK) announced that Edward M. Kaye, M.D., has been appointed to the company's Board of Directors. Dr. Kaye is the Interim Chief Executive Officer and Senior Vice President, Chief Medical Officer of Sarepta Therapeutics.and more »
05/21/16 11:39 AMCytokinetics Appoints Edward M. Kaye, M.D., to Board of Directors - GlobeNewswire (press release) - Cytokinetics Appoints Edward M. Kaye, M.D., to Board of DirectorsGlobeNewswire (press release)SOUTH SAN FRANCISCO, Calif., May 20, 2016 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) announced today that Edward M. Kaye, M.D., has been appointed to the company's Board of Directors. Dr. Kaye is the Interim Chief Executive Officer ...and more »
05/20/16 03:35 PMCYTOKINETICS INC Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submission of M -
05/20/16 03:33 PMCytokinetics Appoints Edward M. Kaye, M.D., to Board of Directors - [at noodls] - SOUTH SAN FRANCISCO, Calif., May 20, 2016 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) announced today that Edward M. Kaye, M.D., has been appointed to the company's Board of Directors. Dr. Kaye ...
05/19/16 11:41 AMHow Many Cytokinetics, Inc. (NASDAQ:CYTK)'s Analysts Are Bullish? - Wall Street Hints and News - How Many Cytokinetics, Inc. (NASDAQ:CYTK)'s Analysts Are Bullish?Wall Street Hints and NewsOut of 5 analysts covering Cytokinetics (NASDAQ:CYTK), 6 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Cytokinetics has been the topic of 5 analyst reports since July 24, 2015 according to StockzIntelligence Inc. Below is a ...Cytokinetics (NASDAQ:CYTK) Short Interest Decreased By 1.11%Franklin Independentall 3 news articles »
05/13/16 03:08 PMCytokinetics Announces Additional COSMIC-HF Results to Be Presented at Heart Failure 2016 - [at noodls] - SOUTH SAN FRANCISCO, Calif., May 13, 2016 (GLOBE NEWSWIRE) -- Cytokinetics, (Nasdaq:CYTK) announced today that a poster presentation on additional results from COSMIC-HF (Chronic Oral Study of Myosin Activation ...
05/11/16 04:07 PMCytokinetics to Hold Annual Meeting of Stockholders - [at noodls] - SOUTH SAN FRANCISCO, Calif., May 11, 2016 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) announced today that its Annual Meeting of Stockholders will be held on Wednesday, May 18, 2016 at 10:30 AM ...
05/05/16 04:04 PMCYTOKINETICS INC Files SEC form 10-Q, Quarterly Report -
05/02/16 06:30 AMCytokinetics to Ring Nasdaq Closing Bell to Launch ALS Awareness Month - [GlobeNewswire] - SOUTH SAN FRANCISCO, Calif., May 02, 2016-- Cytokinetics, Inc. today announced that it will ring the Closing Bell at Nasdaq this afternoon in recognition of ALS Awareness Month and the company’ s commitment ...
05/02/16 05:50 AMCytokinetics's (CYTK) CEO Robert Blum on Q1 2016 Results - Earnings Call Transcript - Seeking Alpha - Cytokinetics's (CYTK) CEO Robert Blum on Q1 2016 Results - Earnings Call TranscriptSeeking AlphaGood afternoon and welcome, ladies and gentlemen, to the Cytokinetics First Quarter 2016 conference call. At this time, I would like to inform you that this call is being recorded and that all participants are in a listen-only mode. [Operator ...The ALS Association and Cytokinetics Ring in May as ALS Awareness Month at NASDAQPR Newswire (press release)all 2 news articles »
04/30/16 05:58 AMRoth Capital Reiterates Buy on Cytokinetics, Inc. (CYTK) Following 1Q16 Update - Smarter Analyst - Web Breaking NewsRoth Capital Reiterates Buy on Cytokinetics, Inc. (CYTK) Following 1Q16 UpdateSmarter AnalystIn a research report published today, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on shares of Cytokinetics Inc. (NASDAQ:CYTK), with a price target of $22, following the company's first-quarter results and update on its pipeline. The ...Cytokinetics, Inc. Reports First Quarter 2016 Financial ResultsGlobeNewswire (press release)Cytokinetics, Inc. (CYTK) Announces Quarterly Earnings Results, Beats Estimates By $0.06 EPSWeb Breaking NewsCytokinetics, Inc. (Nasdaq: CYTK) to Ring The Nasdaq Stock Market Closing BellEIN News (press release)B.O.D.Y Confidential -CWRU Observer -Share Trading Newsall 8 news articles »
04/29/16 03:14 PMEdited Transcript of CYTK earnings conference call or presentation 28-Apr-16 8:30pm GMT -
04/29/16 09:50 AMCytokinetics, Inc. (Nasdaq: CYTK) to Ring The Nasdaq Stock Market Closing Bell - [at noodls] - ADVISORY, April 29, 2016 (GLOBE NEWSWIRE) -- What: Cytokinetics, Inc. (Nasdaq:CYTK), a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle ...
04/29/16 06:21 AMCytokinetics, Inc. Reports First Quarter 2016 Financial Results - GlobeNewswire (press release) - Web Breaking NewsCytokinetics, Inc. Reports First Quarter 2016 Financial ResultsGlobeNewswire (press release)SOUTH SAN FRANCISCO, Calif., April 28, 2016 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) reported total research and development revenues for the first quarter of 2016 were $8.4 million, compared to $4.4 million, during the same period in ...Cytokinetics, Inc. (CYTK) Announces Quarterly Earnings Results, Beats Estimates By $0.06 EPSWeb Breaking NewsEarnings Estimates Report: Cytokinetics, Incorporated (CYTK)CWRU ObserverBroker Roundup For Cytokinetics, Incorporated (NASDAQ:CYTK)Share Trading Newsall 4 news articles »
04/28/16 03:26 PMCytokinetics, Inc. Reports First Quarter 2016 Financial Results - [at noodls] - SOUTH SAN FRANCISCO, Calif., April 28, 2016 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) reported total research and development revenues for the first quarter of 2016 were $8.4 million, compared ...
04/28/16 06:07 AMQ1 2016 Cytokinetics Inc Earnings Release - 4:00 pm ET -
04/14/16 03:25 PMCytokinetics to Announce First Quarter Results on April 28, 2016 - [at noodls] - SOUTH SAN FRANCISCO, Calif., April 14, 2016 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) announced today that it is scheduled to report first quarter results on Thursday, April 28, 2016 at 4:00 ...
04/08/16 09:42 AMCytokinetics (NASDAQ:CYTK) Sellers Increased By 3.85% Their Shorts - RiversideGazette.com - Cytokinetics (NASDAQ:CYTK) Sellers Increased By 3.85% Their ShortsRiversideGazette.comWith 363,800 shares average volume, it will take short sellers 15 days to cover their CYTK's short positions. The short interest to Cytokinetics's float is 18.31%. The stock increased 7.38% or $0.53 during the last trading session, hitting $7.71 ...
04/08/16 09:42 AMCytokinetics Inc (NASDAQ:CYTK) Institutional Investor Sentiment Trend - RiversideGazette.com - Cytokinetics Inc (NASDAQ:CYTK) Institutional Investor Sentiment TrendRiversideGazette.comCytokinetics Inc (NASDAQ:CYTK) institutional sentiment increased to 1.38 in 2015 Q3. Its up 0.04, from 1.34 in 2015Q2. The ratio is better, as 55 active investment managers started new and increased holdings, while 41 sold and reduced their positions ...Iguana Healthcare Management adds Cytokinetics (CYTK) to its portfolioSCSUCollegianBroker Roundup For Cytokinetics, Incorporated (NASDAQ:CYTK)Share Trading Newsall 3 news articles »
04/08/16 09:42 AMCytokinetics Inc (CYTK) Jumps 7.38% on April 06 - Equities.com - Cytokinetics Inc (CYTK) Jumps 7.38% on April 06Equities.comCytokinetics Inc (CYTK) was among the biggest gainers on the Russell 2000 for Wednesday April 06 as the stock popped 7.38% to $7.71, representing a gain of $0.53 per share. Some 286,665 shares traded hands on 1,638 trades, compared with an average ...and more »
04/05/16 03:27 PMCytokinetics to Present at the 15th Annual Needham Healthcare Conference - [at noodls] - SOUTH SAN FRANCISCO, Calif., April 05, 2016 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) announced today that Robert I. Blum, President and Chief Executive Officer, is scheduled to present a corporate ...
04/04/16 01:25 PMCYTOKINETICS INC Files SEC form 8-K, Other Events -
04/04/16 01:15 PMStock Update (NASDAQ:CYTK): Cytokinetics, Inc. Start of Phase 2 Clinical Trial of Omecamtiv Mecarbil in Japanese ... - Smarter Analyst - Smarter AnalystStock Update (NASDAQ:CYTK): Cytokinetics, Inc. Start of Phase 2 Clinical Trial of Omecamtiv Mecarbil in Japanese ...Smarter AnalystCytokinetics, Inc. (NASDAQ:CYTK) announced the start of a double-blind, randomized, placebo-controlled, multi-center Phase 2 clinical trial to evaluate the safety, pharmacokinetics and efficacy of omecamtiv mecarbil in Japanese subjects with heart ...Cytokinetics, Inc. Stock Price Gaps Up Today; Buyers Are ThrivingClinton FinancialTrade-Ideas: Cytokinetics (CYTK) Is Today's Strong On High Relative Volume StockTheStreet.comCytokinetics Starts Phase 2 Testing of Omecamtiv Mecarbil in Heart Failure (NASDAQ:CYTK)Sonoran Weekly Reviewall 5 news articles »
04/04/16 06:57 AMCytokinetics Announces Start of Phase 2 Clinical Trial of Omecamtiv Mecarbil in Japanese Subjects With Heart Failure - [at noodls] - SOUTH SAN FRANCISCO, Calif., April 04, 2016 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) today announced the start of a double-blind, randomized, placebo-controlled, multi-center Phase 2 clinical ...
04/02/16 10:02 AMCytokinetics (NASDAQ:CYTK) Sellers Increased By 3.85% Their Shorts - Clinton Financial - Cytokinetics (NASDAQ:CYTK) Sellers Increased By 3.85% Their ShortsClinton FinancialThe short interest to Cytokinetics's float is 18.31%. The stock increased 1.99% or $0.14 on April 1, hitting $7.19. About 169,078 shares traded hands. Cytokinetics, Inc. (NASDAQ:CYTK) has risen 6.84% since August 26, 2015 and is uptrending.and more »
03/31/16 12:14 PMCYTOKINETICS INC (NASDAQ:CYTK) rating of Maintain confirmed by JP Morgan - Hints News Network - CYTOKINETICS INC (NASDAQ:CYTK) rating of Maintain confirmed by JP MorganHints News NetworkCYTOKINETICS INC (NASDAQ:CYTK) opened at $6.80 on Friday. The firm's 50-day moving average is $6.56 and it's 200-day moving average is $8.47. The business has a market cap of $263.12M and a P/E ratio of . CYTOKINETICS INC has a annual low of ...Analysts update: Jp Morgan rated Cytokinetics Inc (NASDAQ:CYTK) to Lowers,Maintains, Sets Target Price to $14The Duncan Independent (press release) (blog)Morning Broker Update: Cytokinetics, Incorporated (NASDAQ:CYTK)Share Trading NewsStocks Favored by Analysts: Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), Cytokinetics, Incorporated (NASDAQ ...RiversideGazette.comRisers & Fallersall 6 news articles »
03/31/16 12:14 PMStock Update (NASDAQ:CYTK): Cytokinetics, Inc. and Origent Data Sciences Announce Research Collaboration on ... - Smarter Analyst - Smarter AnalystStock Update (NASDAQ:CYTK): Cytokinetics, Inc. and Origent Data Sciences Announce Research Collaboration on ...Smarter AnalystCytokinetics, Inc. (NASDAQ:CYTK) and Origent Data Sciences, Inc. (Origent) announced a research collaboration to refine and prospectively validate an Origent computer model to predict the course of ALS disease progression leveraging data from ...Cytokinetics Collaborating With Origent Data Sciences To Refine Model Of ALS Disease Progression (NASDAQ:CYTK)Sonoran Weekly ReviewOrigent Data Sciences and Cytokinetics Announce Research Collaboration on Predictive Analytics Model in ALSGlobeNewswire (press release)all 3 news articles »
03/31/16 06:59 AMOrigent Data Sciences and Cytokinetics Announce Research Collaboration on Predictive Analytics Model in ALS - [at noodls] - SOUTH SAN FRANCISCO, Calif., March 31, 2016 (GLOBE NEWSWIRE) -- Origent Data Sciences, Inc. (Origent) and Cytokinetics, Inc. (Nasdaq:CYTK) today announced a research collaboration to refine and prospectively ...
03/31/16 06:33 AM7:33 am Cytokinetics and Origent Data Sciences announce a research collaboration to refine and prospectively validate an Origent computer model to analyze the ALS disease progression leveraging data from clinical trials of tirasemtiv -
03/25/16 12:06 PMAnalysts give average Rating of “Buy” to Cytokinetics, Inc. (NASDAQ:CYTK) - MicroCap Magazine - MicroCap MagazineAnalysts give average Rating of “Buy” to Cytokinetics, Inc. (NASDAQ:CYTK)MicroCap MagazineCytokinetics logo Shares of Cytokinetics, Inc. (NASDAQ:CYTK) have received an average recommendation of “Buy” from the eight analysts that are currently covering the firm, Market Beat reports. One investment analyst has rated the stock with a hold ...Cytokinetics, Inc. (NASDAQ:CYTK) Receives Average Rating of "Buy" from AnalystsThe Vista VoiceAnalysts Release New Consensus Estimates for CYTOKINETICS INC (NASDAQ:CYTK)Hints News NetworkCan Shares Of Cytokinetics, Incorporated (NASDAQ:CYTK) Hit $N/A?Stocks DailyRiversideGazette.com -Risers & Fallersall 6 news articles »
03/22/16 10:52 PMCytokinetics Inc (CYTK) Jumps 5.31% on March 21 - Equities.com - Cytokinetics Inc (CYTK) Jumps 5.31% on March 21Equities.comCytokinetics Inc (CYTK) was among the biggest gainers on the Russell 2000 for Monday March 21 as the stock popped 5.31% to $6.54, representing a gain of $0.33 per share. Some 345,935 shares traded hands on 2,347 trades, compared with an average ...and more »
About Cytokinetics

Cytokinetics logoCytokinetics, Incorporated is a biopharmaceutical company. The Company is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions. Its drug candidates include tirasemtiv, CK-2127107 and omecamtiv mecarbil. Its lead drug candidate from its skeletal muscle contractility program, tirasemtiv, is a skeletal muscle troponin activator. The Company is developing CK-2127107, a skeletal muscle troponin activator. The Company has conducted approximately five Phase I clinical trials of CK-2127107. Its lead drug candidate from its cardiac muscle contractility program, omecamtiv mecarbil, is a cardiac muscle myosin activator. COSMIC-HF is a Phase II, double-blind, randomized, placebo-controlled, multicenter, clinical trial designed to assess the pharmacokinetics and tolerability of omecamtiv mecarbil dosed orally in patients with heart failure and left ventricular systolic dysfunction.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: CYTK
  • CUSIP:
Key Metrics:
  • Previous Close: $9.49
  • 50 Day Moving Average: $8.32
  • 200 Day Moving Average: $8.05
  • P/E Ratio: N/A
  • P/E Growth: -0.41
  • Market Cap: $376.00M
  • Current Quarter EPS Consensus Estimate: $-1.50 EPS
Additional Links:
Cytokinetics (NASDAQ:CYTK) Chart for Thursday, June, 30, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha